# Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

> **NCT02999906** · PHASE3 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Oral Treprostinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02999906
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-10
- **Primary completion:** 2021-12
- **Final completion:** 2022-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** For business reasons.
- **Last updated:** 2017-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02999906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02999906, "Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02999906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*